Previous Page  17 / 49 Next Page
Show Menu
Previous Page 17 / 49 Next Page
Page Background



To develop and deliver a new drug development strategy – by disease and across

diseases – based on the specific biology of patients’ tumour, taking into account existing

therapeutic strategies implemented by the ECTGs;


To provide a guide for efficient and innovative public-private partnerships between

academia and the pharmaceutical industry, within the frame of the EU Paediatric Medicine



1. Across Europe, increase the access of patients to new and innovative therapies, including

better referral of patients, and install a molecular and immunological tumour portrait as

a standard of care at the time of relapse as well as at diagnosis for patients with a high-

risk and resistant diseases (link with objective 2);

2. Improve the evaluation of adult cancer drugs for use in the paediatric population,

establishing a clear drugs’ prioritisation and avoiding unjustified waivers (not allowing an

adult drug to be translated to children);

3. Identify targets in paediatric cancers and, thus, develop specific paediatric anti-cancer

drugs (link with objective 3);

4. Develop innovative technologies such a high precision radiation therapy and

interventional radiology;

5. Develop innovative designs and methods for efficient studies, both in early phase and

phase III clinical trials;

6. Influence changes in the relevant regulations;

7. Develop international academic collaboration and efficient cooperation with main

stakeholders (patients, survivors, parents, academia, charities, industry, regulators, EU

decision- and policy-makers).

The European new drug development programme will be implemented by the European

consortium for Innovative Therapies for Children with Cancer (ITCC), in collaboration with the

disease-specific European Clinical Trials Groups (ECTGs).

Brought about by ENCCA, the CDDF (Cancer Drug Development Forum)- SIOPE -ITCC

paediatric oncology platform was created in 2013 with academia, industry, parents and

regulators in order to make proposals for improving new oncology drugs development for

children and adolescents [8].